Abstract:Alport syndrome (AS) is a hereditary kidney disease associated with proteinuria, hematuria and progressive kidney failure. It is characterized by a defective glomerular basement membrane caused by mutations in type IV collagen genes COL4A3/A4/A5 which result in defective type IV collagen α3, α4, or α5 chains, respectively. Alport syndrome has three different patterns of inheritance: X-linked, autosomal and digenic. In a study of CKD of unknown etiology type IV collagen gene mutations accounted for the majority of the cases of hereditary glomerulopathies which suggests that AS is often underrecognized. The natural history and prognosis in patients with AS is variable and is determined by genetics and environmental factors. At present, no preventive or curative therapies exist for AS. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy. Ramipril was found in retrospective studies to delay the onset of ESKD and was recently demonstrated to be safe and effective in children and adolescents, supporting that early initiation of Renin Angiotensin Aldosterone System (RAAS) blockade is very important. Mineralocorticoid receptor blockers might be favorable for patients who develop "aldosterone breakthrough." While the DAPA-CKD trial suggests a beneficial effect of SGLT2 inhibitors in CKD of non-metabolic origin, only a handful of patients had Alport in this cohort, and therefore conclusions can't be extrapolated for the treatment of AS with SGLT2 inhibitors. Advances in our understanding on the pathogenesis of Alport syndrome has culminated in the development of innovative therapeutic approaches that are currently under investigation. We will provide a brief overview of novel therapeutic targets to prevent progression of kidney disease in AS. Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and angiotensin 1 receptor inhibitor; atrasentan, oral selective ETAR inhibitor; lipid-modifying agents, including cholesterol efflux transporter ATP-binding cassette A1 (ABCA1) inducers, discoidin domain receptor 1 (DDR1) inhibitors and osteopontin blocking agents; the antimalarial drug hydroxychloroquine; the antiglycemic drug metformin and the active vitamin D analog paricalcitol. Future genomic therapeutic strategies such as chaperone therapy, genome editing and stem cell therapy will also be discussed.

Alpha lipoic acid as a novel therapeutic approach to cystinuria

Alpha-lipoic acid: A promising pharmacotherapy seen through the lens of kidney diseases

Protective effect of urolithin a on cisplatin-induced nephrotoxicity in mice via modulation of inflammation and oxidative stress

A Summary of Current Guidelines and Future Directions for Medical Management and Monitoring of Patients with Cystinuria

Cystinuria: mechanisms and management

Established and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentarium

Management of cystinuria

Proposal for pathogenesis-based treatment options to reduce calcium oxalate stone recurrence

Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies

Clinical Characteristics and In Silico Analysis of Cystinuria Caused by a Novel SLC3A1 Mutation

Kidney stones: an update on current pharmacological management and future directions

Comprehensive proteomic quantification of bladder stone progression in a cystinuric mouse model using data-independent acquisitions.

Lipidomics Characterization of the Lipid Metabolism Profiles in a Cystinuria Rat Model: Precalculus Damage in the Kidney of Cystinuria.

Renal-Protective Roles of Lipoic Acid in Kidney Disease

The potential role of Sodium/Glucose Cotransporter 2 inhibitors in the treatment of cystinuria

Novel Therapies for Alport Syndrome

Protective Effect of Salvianolic Acid B Against Oxidative Injury Associated with Cystine Stone Formation.

Pathophysiology-based treatment of urolithiasis

Novel Mechanism for Tubular Injury in Nephropathic Cystinosis

Challenges in diagnosis and treatment of cystinuria patients with Urolithiasis: multicenter patient centered study

Plant-based therapies for urolithiasis: a systematic review of clinical and preclinical studies